LR

Lajpat Rai

Active Director Whole-Time Director DIN 09176234
DIN 09176234 First appointment May 2021 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2021
Shareholding value β€’β€’β€’β€’ Premium profile

About Lajpat Rai

Data last updated:

Lajpat Rai is a Whole-Time Director at Labogen Pharma Private Limited (since 2021). The company operates in Chemicals.

DIN 09176234
Primary Designation Whole-Time Director
Industry Chemicals
First Appointment 17 May 2021
Oldest Company Age 5 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Labogen Pharma Private Limited U24299UR2021PTC012412
Whole-Time Director17 May 20212021Active

Board colleagues of Lajpat Rai

NameDINCompanyDesignation
Dinny Gulyani02396609Labogen Pharma Private LimitedWhole-Time Director
Sumit Kumar09176233Labogen Pharma Private LimitedWhole-Time Director

Directorship timeline

Open interactive timeline →
Labogen Pharma Private Limited
Premium access

Shareholding and investment profile for Lajpat Rai

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Lajpat Rai

Lajpat Rai currently holds 1 directorship: Labogen Pharma Private Limited (Whole-Time Director, since 17 May 2021).

Lajpat Rai was first appointed on 17 May 2021 as Whole-Time Director at Labogen Pharma Private Limited.

The current boards of Lajpat Rai's companies include Dinny Gulyani (Labogen Pharma Private Limited), Sumit Kumar (Labogen Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available